TNSN07409A1 - Modulateurs d'androgenes - Google Patents

Modulateurs d'androgenes

Info

Publication number
TNSN07409A1
TNSN07409A1 TNP2007000409A TNSN07409A TNSN07409A1 TN SN07409 A1 TNSN07409 A1 TN SN07409A1 TN P2007000409 A TNP2007000409 A TN P2007000409A TN SN07409 A TNSN07409 A TN SN07409A TN SN07409 A1 TNSN07409 A1 TN SN07409A1
Authority
TN
Tunisia
Prior art keywords
modulators
androgenes
benzonitriles
sebum
aspects
Prior art date
Application number
TNP2007000409A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Victor Fedij
Lain-Yen Hu
Donna Michele Iula
Bruce Allen Lefker
Raj Kumar Raheja
Karen Elaine Sexton
Camp Jennifer Ann Van
Original Assignee
Warner - Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner - Lambert Company Llc filed Critical Warner - Lambert Company Llc
Publication of TNSN07409A1 publication Critical patent/TNSN07409A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne une catégorie nouvelle de benzonitriles et leur utilisation comme modulateurs des récepteurs d'androgènes. D'autres aspects de l'invention concernent l'utilisation de ces composés pour réduire l'excès de sécrétions de sébum et pour stimuler la croissance capillaire.
TNP2007000409A 2005-05-05 2007-11-02 Modulateurs d'androgenes TNSN07409A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67803505P 2005-05-05 2005-05-05
US68211205P 2005-05-18 2005-05-18
PCT/IB2006/001266 WO2006117677A1 (fr) 2005-05-05 2006-04-24 Modulateurs des androgenes

Publications (1)

Publication Number Publication Date
TNSN07409A1 true TNSN07409A1 (fr) 2009-03-17

Family

ID=37023044

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000409A TNSN07409A1 (fr) 2005-05-05 2007-11-02 Modulateurs d'androgenes

Country Status (25)

Country Link
US (2) US7674819B2 (fr)
EP (1) EP1888524A1 (fr)
JP (1) JP4174068B1 (fr)
KR (1) KR20070116970A (fr)
CN (1) CN101166718A (fr)
AP (1) AP1932A (fr)
AR (1) AR053721A1 (fr)
AU (1) AU2006242927A1 (fr)
BR (1) BRPI0610998A2 (fr)
CA (1) CA2603866C (fr)
CR (1) CR9496A (fr)
DO (1) DOP2006000097A (fr)
EA (1) EA200702158A1 (fr)
GT (1) GT200600187A (fr)
IL (1) IL186401A0 (fr)
MA (1) MA29516B1 (fr)
MX (1) MX2007013823A (fr)
NL (1) NL1031752C2 (fr)
NO (1) NO20076026L (fr)
PE (1) PE20061388A1 (fr)
TN (1) TNSN07409A1 (fr)
TW (1) TW200724139A (fr)
UY (1) UY29517A1 (fr)
WO (1) WO2006117677A1 (fr)
ZA (1) ZA200709385B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102990A1 (fr) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Modulateurs des androgenes
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2008066117A1 (fr) 2006-11-30 2008-06-05 Takeda Pharmaceutical Company Limited Composé amine cyclique
KR20100049644A (ko) * 2007-08-07 2010-05-12 다케다 야쿠힌 고교 가부시키가이샤 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체
EP2571864A1 (fr) 2010-05-17 2013-03-27 Array Biopharma, Inc. Lactames à substitution pipéridinyle comme modulateurs de gpr119
HRP20240027T1 (hr) * 2015-05-25 2024-04-26 Suzhou Pengxu Pharmatech Co., Ltd. Postupci za proizvodnju brivaracetama

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298470C (fr)
US6124343A (en) 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US3535365A (en) 1967-11-29 1970-10-20 Merck & Co Inc Preparation of 2,6-dichloro-4-methoxy-benzonitrile
DE2062349A1 (de) 1970-12-18 1972-06-29 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminoaryloxy-ary!carbonsäurenitrile und ein Verfahren zu ihrer Herstellung
SU469247A3 (ru) 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4029493A (en) 1973-02-23 1977-06-14 Mobil Oil Corporation Substituted phenoxybenzonitriles as herbicides
FR2397387A1 (fr) 1976-04-27 1979-02-09 Serobiologiques Lab Sa 4,4'-bis-formyl-polyhalo-diphenoxyalcanes, procede de preparation et application a la synthese de 4,4'-dicyano-polyhalo-diphenoxyalcanes
US4234595A (en) 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
EP0002309B1 (fr) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, procédé pour leur préparation et compositions pharmaceutiques et vétérinaires les contenant
DD150456A5 (de) 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
US4567201A (en) 1981-11-25 1986-01-28 Takeda Chemical Industries, Ltd. Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof
GB8504093D0 (en) 1985-02-18 1985-03-20 Ici Plc Alkene alkyne/cycloalkylene derivatives
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
DE3382646D1 (de) 1982-08-26 1993-01-28 Merck Patent Gmbh Cyclohexanderivate und ihre verwendung als komponenten fluessigkristalliner-dielektrika.
JPS59144747A (ja) 1983-02-04 1984-08-18 Chisso Corp ２−クロロ−４−アルキルオキシベンゾニトリル化合物
US4536321A (en) 1983-02-18 1985-08-20 Chisso Corporation Fluorobenzene derivatives and liquid crystal compositions containing the same
DE3515633A1 (de) 1985-05-02 1986-11-06 Merck Patent Gmbh, 6100 Darmstadt Benzonitrile
PH23700A (en) 1985-10-01 1989-09-27 Ciba Geigy Ag Microbicides
JPS63141967A (ja) 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
JPS63227502A (ja) 1987-03-17 1988-09-21 Sds Biotech Kk 防菌防カビ剤
US4992433A (en) 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
US4925590A (en) 1988-03-10 1990-05-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 4-cyano-2,3-difluorophenol
DE3825170A1 (de) 1988-07-23 1990-01-25 Hoechst Ag, 65929 Frankfurt Substituierte 5-(4-(4,5-dihydro-2-oxazolyl)-phenoxyalkylenoxyalkyl)-isoxazole, verfahren sowie 5-(phenoxyalkylenoxyalkyl)-isoxazole als zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekaempfung von krankheiten, die durch infektion mit viren hervorgerufen wurden
NZ234842A (en) 1989-08-10 1992-06-25 Glaxo Inc Pyridazinone derivatives and pharmaceutical compositions
US5051431A (en) 1989-09-22 1991-09-24 Glaxo Inc. Pyridone nitriles useful in treating cardiovascular disease
DE4017019A1 (de) 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
JPH04124183A (ja) 1990-09-14 1992-04-24 Mitsubishi Rayon Co Ltd 光学活性パントラクトン誘導体
GB9025828D0 (en) 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
JP3088777B2 (ja) 1991-03-27 2000-09-18 富士薬品工業株式会社 新規光学分割剤及びそれを用いる光学活性アミンの製造方法
US5320825A (en) 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
JP3151929B2 (ja) 1992-05-15 2001-04-03 大日本インキ化学工業株式会社 フルオロシクロヘキセン誘導体
DE4217928A1 (de) 1992-05-30 1993-12-02 Hoechst Ag Neue Mischungen aus Herbiziden und Antidots, neue (Hetero-)Aryloxy-Verbindungen, Verfahren zu deren Herstellung, diese enthaltenden Mittel und deren Verwendung
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
EP0659047A1 (fr) 1992-09-09 1995-06-28 E.I. Du Pont De Nemours And Company Composes de benzene herbicides
US5455274A (en) 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5326553A (en) 1993-02-02 1994-07-05 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualization of the gastrointestinal tract
US5316755A (en) 1993-02-02 1994-05-31 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
GB2278054A (en) 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
DE4339863A1 (de) 1993-11-23 1995-05-24 Bayer Ag Substituierte Carbamoyltriazole
TW262553B (fr) 1994-03-17 1995-11-11 Hitachi Seisakusyo Kk
JPH09512029A (ja) 1994-04-21 1997-12-02 ニコメド イマギング アクスイェ セルスカプ 薬理学的に許容される粘土を含むｘ線造影組成物
JPH07309850A (ja) 1994-05-16 1995-11-28 Canon Inc 光学活性化合物、それを含有する液晶組成物、それを有する液晶素子及びそれらを用いた表示方法、表示装置
CA2150326A1 (fr) 1994-05-27 1995-11-28 Kimihiro Murakami Derives azolylmethylphenyle inhibant l'aromatase
PT707007E (pt) 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
JP3802581B2 (ja) 1995-03-01 2006-07-26 富山化学工業株式会社 新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
JPH08325154A (ja) 1995-03-31 1996-12-10 Mitsui Toatsu Chem Inc 安息香酸誘導体およびそれを有効成分として含有するホスホリパーゼａ２阻害剤
DE19534209A1 (de) 1995-09-15 1997-03-20 Jenapharm Gmbh Hormonales Mittel zur Behandlung der Haut
EP0790235A1 (fr) 1996-02-15 1997-08-20 Sankyo Company Limited Dérivés de diaryle-alkanes contenant un groupe alicyclique, leur préparation et leurs applications thérapeutiques et prophylactiques
ES2127106B1 (es) 1996-03-21 1999-11-16 Menarini Lab Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.
DE19612032A1 (de) 1996-03-27 1997-10-09 Basf Ag Substituierte 1-Methyl-3-benzyluracile
JP3515284B2 (ja) 1996-06-24 2004-04-05 カルソニックカンセイ株式会社 車両用エアコンシステムのドア制御装置
JPH107647A (ja) 1996-06-25 1998-01-13 Yamanouchi Pharmaceut Co Ltd 新規なチオ尿素誘導体又はその塩
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
EP1019384A1 (fr) 1997-02-04 2000-07-19 Dong Wha Pharmaceutical Industrial Co. Ltd. Derive 3-amino-1,2-benzoisoxazole, procede de preparation et utilisation
US6013668A (en) 1997-08-13 2000-01-11 Bristol-Myers Squibb Company Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2094700A (en) 1998-12-04 2000-06-26 Basf Aktiengesellschaft Method for producing pyrazolylbenzoyl derivatives and novel pyrazolylbenzoyl derivatives
WO2000034269A1 (fr) 1998-12-09 2000-06-15 American Home Products Corporation Inhibiteurs de thio-uree des virus de l'herpes
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
GB9904786D0 (en) 1999-03-02 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU3931400A (en) 1999-04-02 2000-10-23 Neurogen Corporation N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
AU2001234689A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Bivalent phenylene inhibitors of factor xa
WO2002006196A1 (fr) 2000-07-13 2002-01-24 Merck Patent Gmbh Composes chiraux i
SK2012003A3 (en) 2000-08-31 2004-06-08 Pfizer Phenoxybenzylamine derivatives as selective re-uptake inhibitors
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
US7115663B2 (en) 2000-09-06 2006-10-03 Emisphere Technologies, Inc. Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
DE60135764D1 (de) 2000-10-06 2008-10-23 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
JP2004513134A (ja) 2000-10-12 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
AU2002220715A1 (en) 2000-11-24 2002-06-03 Smithkline Beecham Plc Indolsulfonyl compounds useful in the treatment of cns disorders
AU2002236775A1 (en) 2001-01-16 2002-07-30 Seok-Ki Choi Sodium channel modulators
OA12541A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Ether derivatives useful as inhibitors of PDE4 isozymes.
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
PL217629B1 (pl) 2001-04-10 2014-08-29 Pfizer Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
DE10126434A1 (de) 2001-05-31 2002-12-05 Bayer Ag Thiochromenone
GB0202679D0 (en) 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
BRPI0307699A2 (pt) 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
CA2474171A1 (fr) 2002-02-15 2003-08-21 Endorecherche, Inc. Derives biphenyle et leur utilisation comme agents anti-androgeniques
KR20040104463A (ko) 2002-02-28 2004-12-10 유니버시티 오브 테네시 리서치 파운데이션 비가역적 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법
CA2477764A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
EP1348701A1 (fr) 2002-03-28 2003-10-01 Warner-Lambert Company LLC Thiazol-5-yl-amines 2,4-disubstituées comme inhibiteurs de la PDE7
EP1348433A1 (fr) 2002-03-28 2003-10-01 Warner-Lambert Company LLC Thiazol-2-yl-imines comme inhibiteurs de la PDE7
US6875438B2 (en) 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
DE10218963A1 (de) * 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
EP1534714B1 (fr) 2002-08-14 2007-05-16 Ciba SC Holding AG Afficheur a cristaux liquides et filtre couleur presentant une transparence amelioree a la lumiere verte
WO2004018386A2 (fr) 2002-08-26 2004-03-04 Merck & Co., Inc. Potentialisateurs acetophenones des recepteurs metabotropiques du glutamate
EP1638932A1 (fr) 2003-06-18 2006-03-29 Pfizer Products Inc. Nouveaux lactames de piperazinyl-aryloxy et de piperazinyl-heteroaryloxy-n-aryle
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20070129409A1 (en) 2003-11-20 2007-06-07 Lain-Yen Hu Androgen receptor modulators
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
CA2563291A1 (fr) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Derives de 4-cyanophenoxy-alkylcarboxyle comme modulateurs androgenes
WO2005102990A1 (fr) * 2004-04-22 2005-11-03 Warner-Lambert Company Llc Modulateurs des androgenes
CN1980889B (zh) 2004-05-07 2010-11-10 詹森药业有限公司 11-β羟基类固醇脱氢酶抑制剂的金刚烷基吡咯烷-2-酮衍生物
BRPI0513020A (pt) * 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
MX2007001993A (es) * 2004-08-18 2007-05-10 Warner Lambert Co Moduladores de androgenos.
WO2006018732A1 (fr) 2004-08-18 2006-02-23 Warner-Lambert Company Llc Modulateurs d'androgenes
ATE392419T1 (de) * 2004-08-31 2008-05-15 Warner Lambert Co Androgenmodulatoren
WO2006049952A1 (fr) 2004-10-29 2006-05-11 Eli Lilly And Company Inhibiteurs de la 11-béta-hydroxystéroïde déshydrogénase 1 dérivés de cycloalkyllactames
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators

Also Published As

Publication number Publication date
MX2007013823A (es) 2008-02-05
AR053721A1 (es) 2007-05-16
CA2603866C (fr) 2011-05-31
GT200600187A (es) 2006-11-28
WO2006117677A1 (fr) 2006-11-09
TW200724139A (en) 2007-07-01
US20070072936A1 (en) 2007-03-29
US20060252796A1 (en) 2006-11-09
BRPI0610998A2 (pt) 2010-08-10
MA29516B1 (fr) 2008-06-02
ZA200709385B (en) 2008-10-29
CR9496A (es) 2007-12-04
AP2007004197A0 (en) 2007-10-31
NO20076026L (no) 2007-11-22
US7674819B2 (en) 2010-03-09
JP2008540397A (ja) 2008-11-20
CA2603866A1 (fr) 2006-11-09
DOP2006000097A (es) 2006-11-15
AU2006242927A1 (en) 2006-11-09
JP4174068B1 (ja) 2008-10-29
PE20061388A1 (es) 2007-01-15
NL1031752C2 (nl) 2007-03-19
EA200702158A1 (ru) 2008-08-29
US7799823B2 (en) 2010-09-21
NL1031752A1 (nl) 2006-11-13
AP1932A (en) 2008-12-15
IL186401A0 (en) 2008-01-20
EP1888524A1 (fr) 2008-02-20
UY29517A1 (es) 2006-11-30
CN101166718A (zh) 2008-04-23
KR20070116970A (ko) 2007-12-11

Similar Documents

Publication Publication Date Title
TNSN07409A1 (fr) Modulateurs d'androgenes
TW200605876A (en) Androgen modulators
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
FR2938437B1 (fr) Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
MX2007014444A (es) Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TW200626559A (en) Anilino-pyrimidine analogs
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
DK1696905T3 (da) Substituerede 2-aminotetraliner til forebyggende behandling af Morbus Parkinson
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
EA200702455A1 (ru) Модуляторы индоламин 2,3-диоксигеназы и способы их применения
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
TW200719897A (en) Diarylsulfone sulfonamides and use thereof
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
DE60233516D1 (de) Verbesserungen betreffend optische aufheller
WO2006018723A3 (fr) Modulateurs des androgenes
EA200601267A1 (ru) Модуляторы рецепторов андрогена
FR2906716B1 (fr) Utilisation d'une composition cosmetique pour le soin des peaux grasses.
ATE452882T1 (de) Herstellung von quetiapin
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
MA32617B1 (fr) Traitement de l'hypertension arterielle pulmonaire
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas